Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Sponsor: University of Palermo
Summary
The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for acute exacerbation of heart failure, in determining a significant increase in diuresis and natriuresis. It is also accompanied by a rapid reduction in body weight and a substantial decrease in hospitalization length without compromising renal function.
Official title: Enhanced Diuresis and Natriuresis in Acute Decompensated Heart Failure Patients Treated With SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution: A Clinical Trial
Key Details
Gender
All
Age Range
40 Years - 89 Years
Study Type
INTERVENTIONAL
Enrollment
544
Start Date
2024-06
Completion Date
2026-03-30
Last Updated
2024-06-06
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin tablet
Dapagliflozin 10 mg 1 tablet once daily
Hypertonic Saline Solution, 1 Ml
Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
Furosemide Injection
Furosemide 20 mg